|
WO2021073593A1
|
|
Aminopyrimidine compound as cdk2/4/6 triple inhibitor
|
|
WO2021073592A1
|
|
Salt types, crystal forms, and preparation methods for benzopyrazole compounds as rho kinase inhibitors
|
|
WO2021068952A1
|
|
Benzodihydropyran compound targeting aldo-keto reductase 1c3
|
|
WO2021063404A1
|
|
Compound as small molecule inhibitor pd-1/pd-l1 and application thereof
|
|
WO2021058024A1
|
|
Lsd1 inhibitor
|
|
WO2021057893A1
|
|
Pyrazolopyridine compounds as selective btk kinase inhibitors
|
|
WO2021057890A1
|
|
2h-benzopyran derivatives as crac inhibitors
|
|
WO2021047674A1
|
|
Bicyclic compound that acts as crbn protein regulator
|
|
WO2021047627A1
|
|
Fused cyclic compound capable of degrading protein and use thereof
|
|
WO2021037156A1
|
|
Crystal of carcinogenic fused kinase inhibitor and applications thereof
|
|
WO2021032170A1
|
|
Tetracyclic compound used as cdc7 inhibitor
|
|
WO2021023271A1
|
|
Crystal form of compound as prostacyclin receptor agonist and preparation method therefor
|
|
WO2021018298A1
|
|
Indolo-seven-membered acyloxime compounds as parp inhibitors
|
|
WO2021018047A1
|
|
Pyridine derivative as fgfr and vegfr dual inhibitors
|
|
WO2021018044A1
|
|
Sglt2/dpp4 inhibitor and application thereof
|
|
WO2021018017A1
|
|
Pyrimidine compound acting on egfr and erbb2
|
|
WO2021018046A1
|
|
Sglts/dpp4 inhibitor and application thereof
|
|
WO2021013209A1
|
|
Macrocyclic derivatives as factor xia inhibitors
|
|
WO2021004531A1
|
|
Crystalline form of cxcr2 antagonist and application thereof
|
|
WO2021004533A1
|
|
Oxazole compound as multi-targeted inhibitor of irak4 and btk
|
